HomeCompareBRNHF vs ARCC

BRNHF vs ARCC: Dividend Comparison 2026

BRNHF yields 2500.00% · ARCC yields 10.65%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BRNHF wins by $80609755877.34M in total portfolio value
10 years
BRNHF
BRNHF
● Live price
2500.00%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$80609755877.37M
Annual income
$74,729,580,081,858,750.00
Full BRNHF calculator →
ARCC
Ares Capital Corporation
● Live price
10.65%
Share price
$18.02
Annual div
$1.92
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$24.5K
Annual income
$1.14
Full ARCC calculator →

Portfolio growth — BRNHF vs ARCC

📍 BRNHF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBRNHFARCC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BRNHF + ARCC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BRNHF pays
ARCC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BRNHF
Annual income on $10K today (after 15% tax)
$212,500.00/yr
After 10yr DRIP, annual income (after tax)
$63,520,143,069,579,940.00/yr
ARCC
Annual income on $10K today (after 15% tax)
$905.66/yr
After 10yr DRIP, annual income (after tax)
$0.97/yr
At 15% tax rate, BRNHF beats the other by $63,520,143,069,579,940.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BRNHF + ARCC for your $10,000?

BRNHF: 50%ARCC: 50%
100% ARCC50/50100% BRNHF
Portfolio after 10yr
$40304877938.70M
Annual income
$37,364,790,040,929,380.00/yr
Blended yield
92.71%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ARCC right now

BRNHF
No analyst data
Altman Z
1.0
Piotroski
3/9
ARCC
Analyst Ratings
24
Buy
7
Hold
Consensus: Buy
Price Target
$21.88
+21.4% upside vs current
Range: $21.00 — $23.00
Altman Z
0.8
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BRNHF buys
0
ARCC buys
13
PoliticianChamberTickerTypeAmountDate
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-09-09
John Fetterman🏛 Senate$ARCC▼ Sell$1,001 - $15,0002025-09-04
Ashley Moody🏛 Senate$ARCC▲ Buy$15,001 - $50,0002025-04-04
John Fetterman🏛 Senate$ARCC▲ Buy$1,001 - $15,0002025-02-18
Dave McCormick🏛 Senate$ARCC▲ Buy$250,001 - $500,0002025-01-17
Pete Sessions🏢 House$ARCC▼ Sell$1,001 - $15,0002023-11-01
Pete Sessions🏢 House$ARCC▲ Buy$569.252023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-10-06
Pete Sessions🏢 House$ARCC▲ Buy$155.922023-08-15
Pete Sessions🏢 House$ARCC▲ Buy$0 - $1,0002023-08-15
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBRNHFARCC
Forward yield2500.00%10.65%
Annual dividend / share$2.00$1.92
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%-50%
Portfolio after 10y$80609755877.37M$24.5K
Annual income after 10y$74,729,580,081,858,750.00$1.14
Total dividends collected$80198875900.38M$1.1K
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: BRNHF vs ARCC ($10,000, DRIP)

YearBRNHF PortfolioBRNHF Income/yrARCC PortfolioARCC Income/yrGap
1← crossover$260,700$250,000.00$11,373$532.74+$249.3KBRNHF
2$6,370,070$6,091,121.50$12,608$279.46+$6.36MBRNHF
3$145,912,632$139,096,656.81$13,809$142.90+$145.90MBRNHF
4$3,133,830,814$2,977,704,297.75$15,042$72.20+$3133.82MBRNHF
5$63,122,812,060$59,769,613,088.96$16,341$36.27+$63122.80MBRNHF
6$1,192,683,724,131$1,125,142,315,226.76$17,732$18.18+$1192683.71MBRNHF
7$21,144,559,711,004$19,868,388,126,183.19$19,231$9.10+$21144559.69MBRNHF
8$351,818,906,448,043$329,194,227,557,269.44$20,851$4.55+$351818906.43MBRNHF
9$5,495,491,397,671,320$5,119,045,167,771,913.00$22,605$2.28+$5495491397.65MBRNHF
10$80,609,755,877,367,070$74,729,580,081,858,750.00$24,504$1.14+$80609755877.34MBRNHF

BRNHF vs ARCC: Complete Analysis 2026

BRNHFStock

Broncus Holding Corporation, a medical device company, focuses on the development of interventional pulmonology products in Mainland China, the European Union, the United States, and internationally. The company provides navigation products, such as LungPoint Virtual Bronchoscopic Navigation, a computer-assisted image-based navigation software system; LungPoint Plus, a system that provides real-time navigation within the airways for lung biopsy and other procedures; and LungPro, a virtual bronchoscopic navigation product that provides three-dimensional real-time guided transbronchial needle aspiration and proprietary parenchymal navigation. It also offers treatment products comprising InterVapor, a targeted bronchoscopic thermal vapor ablation to ablate the diseased hyper-inflated lung segments; RF Generator + RF Ablation Catheter, a radiofrequency ablation system used in conjunction with a disposable lung radiofrequency ablation catheter, as well as radiofrequency ablation system that targets lung cancer; and H-Marker, a pulmonary surgical marker. In addition, the company provides treatment products, such as BioStarNeedle, a single use ultrasound-guided aspiration needle for retrieval of tissue samples; FleXNeedle, a multipurpose biopsy needle; Archimedes Sheath, a sterile single-use flexible tube that provides a working channel during a bronchoscopic procedure; Archimedes Dilation Balloon, a sterile single-use flexible tube with a balloon at or near the distal tip that is inserted through the bronchoscope or sheath and used to dilate the target lung tissue of the bronchial tree; and Steerable Sheath, a steerable sheath adjustment handle and a working channel. Broncus Holding Corporation was incorporated in 2012 and is headquartered in Hangzhou, China.

Full BRNHF Calculator →

ARCCBDC

Ares Capital Corporation is a business development company specializing in acquisition, recapitalization, mezzanine debt, restructurings, rescue financing, and leveraged buyout transactions of middle market companies. It also makes growth capital and general refinancing. It prefers to make investments in companies engaged in the basic and growth manufacturing, business services, consumer products, health care products and services, and information technology service sectors. The fund will also consider investments in industries such as restaurants, retail, oil and gas, and technology sectors. It focuses on investments in Northeast, Mid-Atlantic, Southeast and Southwest regions from its New York office, the Midwest region, from the Chicago office, and the Western region from the Los Angeles office. The fund typically invests between $20 million and $200 million and a maximum of $400 million in companies with an EBITDA between $10 million and $250 million. It makes debt investments between $10 million and $100 million The fund invests through revolvers, first lien loans, warrants, unitranche structures, second lien loans, mezzanine debt, private high yield, junior capital, subordinated debt, and non-control preferred and common equity. The fund also selectively considers third-party-led senior and subordinated debt financings and opportunistically considers the purchase of stressed and discounted debt positions. The fund prefers to be an agent and/or lead the transactions in which it invests. The fund also seeks board representation in its portfolio companies.

Full ARCC Calculator →
📬

Get this BRNHF vs ARCC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BRNHF vs SCHDBRNHF vs JEPIBRNHF vs OBRNHF vs KOBRNHF vs MAINBRNHF vs HTGCBRNHF vs GBDCBRNHF vs ORCC

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.